This trial is evaluating whether Selexipag will improve 1 primary outcome in patients with Hypertension. Measurement will happen over the course of Up to week 26, within 2-5 hours post-dose.
This trial requires 74 total participants across 2 different treatment groups
This trial involves 2 different treatments. Selexipag is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
Hypertension is associated with a number of environmental exposures such as physical activity, alcohol use, smoking, diet, body weight and a number of psychosocial factors such as stress. It seems that both genetic and physiological factors are at least partially responsible for establishing hypertension.
The prevalence of hypertension is quite high in this cohort of US adults. The prevalence of hypertension among whites older than age 40 is 3.2 times higher than that among nonwhites.
Hypertension is usually an insidious disease that presents gradually. Hypertension, like any chronic diseases, causes a multitude of nonspecific signs and symptoms, some of which may present years before the diagnosis of hypertension is suspected. Most common complaints are: headache, visual problems, dizziness and fatigue. For this reason, a comprehensive assessment is essential.
The cardiovascular system is subject to the action of the renal system. Both the kidneys and the brain are involved in the regulation of blood pressure dynamics to maintain homeostatic pressure in healthy individuals.
What options are available for treatment of hypertension? This review shows that some of the common treatments used for hypertension are effective, but a higher use of medications such as amlodipine and alpha-blockers might increase mortality.
Hypertension may not be "cured." However, the results of recent studies suggest that blood pressure-lowering medications can be effective in the control of blood pressure.
The dose-range examined in this study supports its potential usefulness for reducing PE, for which it may be indicated for patients suffering from severe PE, in whom PE-lowering drug therapy is contraindicated, and on which it may prove effective by decreasing the frequency of PE events and thereby enhancing health status of patients. Considering the well-characterized clinical safety profile of selexipag, this drug may represent an attractive, new option for treatment of severe PE, offering clinicians a new mechanism for reducing its frequency and severity. The observed reduction in PE events is in line with the clinical efficacy of non-selective, short-acting PPARgamma ligands as an add-on to statin treatment.
Although selexipag was not found to be more effective on the primary outcome in the main SEARCH trial over placebo in people with heart failure, in a follow-up of individuals in both treatment arms this result was supported in a meta-analysis.
Selexipag is a selective and irreversible antagonist of the imidazoline receptor I at doses clinically achievable in humans. Selexipag has no cardiovascular effects when dosed in normal subjects or those with mild to moderate hypertension [HbA (1c) ≥ 7 %]. Oral selexipag has a short half-life (30 hr) with little food-related reduction in AUC values at the steady-state pharmacodynamic dose of selexipag 50 mg twice daily.
Sipagliflozin and selexipag offer a broader range of therapeutic opportunities than first-generation SGLT2 receptor inhibitors and represent a new exciting class of therapeutically useful drugs. Further clinical investigation is required to fully characterize the pharmacology of such drugs.
Hypertension is a common problem, especially in older adults and black individuals. So the key to fight hypertension is to monitor and treat hypertension in people with all age (age doesn’t define it). The most prevalent ages is between 40 to 49 years old. The key to fight hypertension may be the diet and exercise habits.
selexipag is well tolerated in the short term in people irrespective of baseline blood pressure. The study will examine the impact and safety of selexipag in people with hypertension over a greater period of time.